ArticleBlood2017
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Margaret Nieborowska-Skorska et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
54 papers cite it
this papertrialcites it